



**World Dementia  
Council** Leading the Global Action  
Against Dementia


# **Global dialogue on dementia and health system readiness: Agenda and participants**

**The dementia landscape  
project**

**7 July 2021**



# Logistics and agenda



**Wednesday 7 July 2021**


Virtual meeting

08:00 PDT      San Francisco  
10:00 CDT      Chicago  
11:00 EDT      New York  
16:00 BST      London  
17:00 CEST     Central Europe



| Section               | Speaker(s)  |
|-----------------------|---|
| Welcome               | Lenny Shallcross  |
| Opening remarks       | Dr Peggy Hamburg  |
| Opening presentations | Chaired by Professor Howard Bergman<br><br>Dr Joanne Pike<br><br>Fiona Carragher<br><br>Dr Maria Tome |
| Group conversation    | Introduced and moderated by<br>Dr Peggy Hamburg   |
| Closing perspectives  | Professor Howard Bergman  |
| Closing thanks        | Lenny Shallcross  |

# Co-chairs



## Dr Margaret Hamburg

Dr Margaret (Peggy) A. Hamburg is an internationally recognised leader in public health and medicine. She is the former Commissioner of the US Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service. Peggy Hamburg is Chair of the American Association for the Advancement of Science and is an elected member of the Council on Foreign Relations and the National Academy of Sciences, where she serves as Foreign Secretary. She currently sits on the board of the Commonwealth Fund, the Simons Foundation, the Urban Institute and the American Museum of Natural History. She is also a member of the Harvard University Global Advisory Council and the Scientific Advisory Committee for the Bill and Melinda Gates Foundation.




## Professor Howard Bergman

Dr Howard Bergman is Professor of Family Medicine, Medicine (Geriatrics), and Oncology, and Assistant Dean, International Affairs, Faculty of Medicine, McGill University. In 2009, at the request of the Quebec Minister of Health, he authored the Quebec Alzheimer Plan and is presently working with the Quebec ministry of health and social services on its implementation. He co-created and co-leads with Professor Isabelle Vedel, the Canadian team for healthcare services/system improvement in dementia care (ROSA research team). In 2018-19, he chaired the Canadian Academy of Health Sciences Panel of 6 experts for the Assessment of Evidence and Best Practices for the development of a Canadian Dementia Strategy, assembled at the request of Public Health Agency of Canada.



# Speakers



## Dr Joanne Pike


Dr Joanne Pike, DrPH, is the chief strategy officer of the Alzheimer's Association. In this role she oversees the Association's strategic plan to advance risk reduction, care and support, research, advocacy, diversity and inclusion, concern and awareness, and fundraising. During her 25 years in progressive leadership in social support and public health, Dr. Pike has developed and executed successful health-focused initiatives while implementing revenue strategies to support those outcomes. At the Alzheimer's Association, she oversees care and support services offered across the organization to those affected by the disease; outreach aimed at creating partnerships with health systems, physicians and other health care professionals; long-term care initiatives focused on person-centered care delivery models; and growth strategies for reaching more individuals through quality improvement, education, and supportive programs and services.



## Fiona Carragher

As Alzheimer's Society's Director of Research and Influencing, Fiona plays a pivotal role in the Society vision to create a world without dementia. Fiona has overall responsibility for our Research and Influencing strategy; leading our growing and ambitious world-class research programme and portfolio and our work to strengthen our position as the national charity leader on dementia health, social care policy and societal change. Prior to joining Alzheimer's Society, Fiona was the Deputy Chief Scientific Officer for NHS England, providing leadership for the 50,000 healthcare science professionals in the NHS and expert advice to the health system on science, innovation and diagnostics. She led a broad portfolio of policy responsibilities including establishing the UK Antimicrobial Resistance Diagnostics programme and the system wide Action Plan on Hearing Loss. She is a passionate advocate for women in health and led the establishment of the first Women in Science and Engineering fellowship programme in the NHS.





### **Dr Maria Tome**

Dr. Tome serves as Senior Scientific Officer at the Product Development and Scientific Support Department of the European Medicines Agency (EMA). EMA can provide medicine developers advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. EMA provides scientific advice and qualification of novel methodologies to support the timely and sound development of high-quality, effective and safe medicines, for the benefit of patients.




### **Lenny Shallcross**

Lenny Shallcross is executive director at the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society he worked in the UK government as a political adviser at the Department for Culture, Media and Sport and the Department of Health, as well as working in Parliament and for the Labour Party.



# Discussion participants



## Zadem Aicha

Regional Public Health  
Department, Algiers


Holder of a doctorate in medicine at the University of Algiers (2007 Algeria), I completed a specialization in geriatrics at the University of Medicine of Nice Sophia Antipolis (2013). My master's thesis in gerontology focused on the management of dementias in Algeria and was the subject of a presentation at the 10th French-speaking congress of geriatrics (Liège 2013) Since I started a Master in drug development at University of Montreal (in progress). I first worked as an oncology assistant (2008-2009), then emergency doctor (2010-2013), and turned to the pharmaceutical field as coordinator of the drug monitoring unit at the Central Pharmacy of Algiers Hospitals (2010-2015). Currently, I am in the regional public health department, infection prevention and control department, for the management of COVID-19 outbreaks in CHSLDs and private residences for the elderly.



## Sameera Al Tuwajiri

Global Lead on  
Population and  
Development at the  
Health Nutrition and  
Population Global  
Practice, World Bank

Sameera Al Tuwajiri is the Global Lead on Population and Development at the Health Nutrition and Population Global Practice of the World Bank. She is a board -certified OB/ GYN with over 10 years of experience in clinical practice before she embarked on studying Public Health. She has a master's in public health from Harvard University, a Ph.D. in health policy and a post-doctoral fellowship from Johns Hopkins. For over a decade now, she has been working on reproductive health and women empowerment. Prior to joining the World Bank in 2010, she was the regional adviser, RH policy for UNFPA, Arab States, the director of the ILO's program on Public Health and Safety and just returned from an external service assignment where she served as the first regional director, Arab States, UN Women.



## Professor Ricardo Allegri

Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre, FLENI


Professor Ricardo F. Allegri is Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre at the Neurological Research Institute Raúl Carrea (FLENI) in Buenos Aires. He is also Professor of Neurology in the School of Medicine at the University of Buenos Aires and is chair of the Scientific Council at the Association against Alzheimer's disease and related disorders in Argentina (ALMA). Professor Allegri has published extensively on cognitive neurology in neurological journals and books and has co-edited seven books, including, "Dementia: A Multidisciplinary Approach," one of the most important books written in Spanish on this topic. He has received over 45 awards in the field of Cognitive Neurology and Neuropsychiatry, including the National Academy of Medicine Award in 2006 and the Research Recognition Award by the School of Medicine, University of Buenos Aires in 2014.



## Professor Gustavo Alves

Vice President of SBRAFH (Brazilian Society of Hospital Pharmacy)

Biochemical Pharmacist; Doctor in Biotechnology. Master in Pharmacy. Post-Doc from the Faculty of Medicine of USP in Ribeirão Preto, Brazil. Member of ISTAART – Alzheimer's Association International Society for advance Alzheimer's Research and Treatment. Member of ASHP - American Society of Health-System Pharmacists. Postgraduate degree in Hospital Pharmacy from Faculdades Oswaldo Cruz. Courses in Hospital Pharmacy in France and Clinical Pharmacy in the United States. University of Chicago Neurobiology Course. Coordinator of the Pharmaceutical Care Group for the Elderly at CRF-SP (Regional Council of Pharmacy) – 2016-current. Vice President of SBRAFH (Brazilian Society of Hospital Pharmacy) – Regional S. Paulo (2011-2012) Coordinator and professor (Pharmacology) of Faculdades Oswaldo Cruz. Author of books in the Pharmacy and Alzheimer's segment. Director of the website [www.farmaciahospitalar.com](http://www.farmaciahospitalar.com)"



## **Matthew Baumgart**

Vice president of Health Policy, Alzheimer's Association


Matthew Baumgart is vice president of Health Policy for the Alzheimer's Association, leading a range of projects at the intersection of policy and programs to achieve an aggressive agenda that serves all those affected by the disease. In this role, he heads the BOLD Public Health Center of Excellence on Dementia Risk Reduction, funded by the CDC. In addition, Baumgart directs the Association's global public policy efforts, working in collaboration with Alzheimer Disease International, the World Dementia Council and the World Health Organization. Baumgart joined the Association in 2009 and has served in roles overseeing policy development, public health policy initiatives, federal affairs and state government affairs. Prior to joining the Association, Baumgart spent nearly 20 years working in the U.S. Senate in a variety of roles, including legislative director for Sen. Barbara Boxer (D-Calif.) and legislative assistant for over a decade to Sen. Joe Biden (D-Del.).



## **Professor Paulo Caramelli**

Professor of Neurology at the Faculty of Medicine of the Federal University of Minas Gerais (UFMG)

Paulo Caramelli obtained his MD degree in 1987 at the University of São Paulo (USP) School of Medicine, in São Paulo, Brazil and completed the residency program in Neurology at the same institution in 1991. Research fellow at the University of Montréal, Canada, from 1992 to 1994. In 1997, he completed a PhD in Neurological Sciences at USP. He is currently Professor of Neurology at the Faculty of Medicine of the Federal University of Minas Gerais (UFMG) and Coordinator of the Behavioral and Cognitive Neurology Research Group at UFMG, in Belo Horizonte, Brazil. Member of the International Working Group on Neurocognitive Disorders of the World Health Organization for the Revision of ICD-11 (2011 – 2017). Current member of the Advisory Council of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). Editor of *Arquivos de Neuro-Psiquiatria*. Associate editor of *eNeurologicalSci* and *Journal of Alzheimer's Disease*, as well as member of the editorial board of the *European Journal of Neurology* and *Neurological Sciences*. His research activities are focused on epidemiological, clinical and translational studies on brain aging, cognitive impairment and dementia.



### **Dr Christopher Chen**

Associate Professor,  
National University of  
Singapore


Dr Christopher Chen is a Senior Clinician-Scientist at the Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, and Director of the Memory Aging and Cognition Centre. His early medical and research training was at Cambridge, Oxford and the Institute of Neurology, London. Since returning to Singapore, Dr Chen has developed multi-disciplinary research programmes with extensive international collaborations. His major research and clinical interests are in neuroimaging, molecular biology and treatment of stroke and dementia. He has published over 390 peer reviewed papers, is the PI for several studies with cognitive outcomes, serves on journal editorial boards and has been a member of trial steering committees and advisory panels. Currently he is President of the Asian Society Against Dementia, Secretary-Treasurer of the Asian & Oceanian Association of Neurology and past-chair of the International Society for Vascular Behavioural and Cognitive Disorders."



### **Dr Howard Chertkow**

Director, Kimel Family  
Centre for Brain Health  
and Wellness, Baycrest


Dr Howard Chertkow joined Baycrest and the University of Toronto from Montreal's McGill University, where he served as Director of the Jewish General Hospital (JGH) and McGill University Bloomfield Centre for Research in Aging and was a Senior Investigator in the Lady Davis Institute for Medical Research. In his practice at the JGH, Dr Chertkow diagnosed and treated patients with early stage Alzheimer's disease and other dementias, and helped found and direct Canada's largest memory clinic. Dr Chertkow will direct the new Kimel Family Centre for Brain Health and Wellness, a research, education and clinical interdisciplinary program to develop and evaluate the most promising approaches to preventing cognitive decline. As its inaugural Director, Dr Chertkow will assemble a state-of-the-art Clinical Trials Unit and further develop Baycrest's translational research program in dementia to test the latest emerging therapies for Alzheimer's disease and related conditions. He will also serve as a Clinical Advisor to the Centre for Aging + Brain Health Innovation (CABHI), the largest venture of its kind in the global seniors' care sector.



### **Dr Yves Couturier**

Scientific director,  
Réseau de  
connaissances sur les  
soins primaires


Yves Couturier, MSW, PhD (Applied Human Sciences) is affiliated with the Social Work Department at the Université de Sherbrooke (Canada). His research expertise is related to integrated services, interprofessional collaboration, and sociology of professional practices in the field of health and social services. He study the implementation of the Alzheimer plan in Québec. He is the scientific director of Réseau de connaissances sur les soins primaires <http://reseau1quebec.ca/> founded by FRQS and CHIR.



### **Professor Jeffrey Cummings**

Founding Director,  
Cleveland Clinic Lou  
Ruvo Center for Brain  
Health

Jeffrey Cummings, MD, ScD, is Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health. He is the Joy Chambers- Grundy Professor of Brain Science, Vice Chair for Research, and Director of the Chambers-Gundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr Cummings is a world-renowned Alzheimer's researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer's disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field.



### **Professor AB Dey**

Founder Head of the Department of Geriatric Medicine in AIIMS, New Delhi


Professor AB Dey was the Founder Head of the Department of Geriatric Medicine in AIIMS, New Delhi. Dr Dey has been working for over 25 years to establish “Old Age Care” as a distinct specialty of medicine in India. Prof Dey has carried out several funded and non funded research projects and published extensively on various aspects of old age health and health care. He is associated with NIH funded study “Harmonized Diagnostic Assessment of Dementia (DAD) for Longitudinal Aging Study of India (LASI)” in collaboration with University of Southern California, Los Angeles; as its Indian Principal Investigator. This longitudinal study has now been extended to second wave. Dr Dey has been assisting the World Health Organization in developing policies and programs in old age care in India and countries in South East Asia, Eastern Mediterranean and Western Pacific Region for last two decades.



### **Dr Harris Eyre**

Co-Founder, PRODEO Institute

Harris A. Eyre MD PhD, Co-Founder, PRODEO Institute: Harris is a brain health executive working to improve outcomes for late-life mood and cognitive disorders. He is president of PRODEO, which advances the commercialization of deep technology solutions. He is co-lead of the OECD-PRODEO Institute Neuroscience-inspired Policy Initiative, which seeks to place ‘brain capital’ at the centre of economic and societal activities. Harris has co-developed and published novel models for late-life innovation including ‘brain health living labs’, ‘late-life brain health architecture’, ‘late-life pharmacogenetics’, ‘brain health diplomacy’ and ‘convergence late-life brain health’. He is an innovation advisor to the American Psychological Association and instructs the brain health diplomacy course for the Global Brain Health Institute.



## Phyllis Ferrell

Global Head of External Engagement for Alzheimer's Disease and Neurodegeneration, Eli Lilly & Company


Phyllis Ferrell is the Global Head of External Engagement for Alzheimer's disease and Neurodegeneration at Eli Lilly & Company, where she previously served as the leader of the Global Alzheimer's disease development team. Ferrell's most recent prior position was Vice President of the Chief Commercial Services Officer for Eli Lilly and Company. Ferrell has been with Lilly for more than 25 years and has held many leadership roles throughout the organization. She has led efforts in medical affairs, medical development, commercial capabilities, sales, marketing, recruiting, business development, strategy, transformation, Six Sigma, and corporate financial planning. Ferrell received a Bachelor of Arts degree in economics and management with minors in computational mathematics and Asian studies from DePauw University. She graduated Phi Beta Kappa and with Magna Cum Laude honors in 1994. She received an MBA in general management and a certificate in public management from the Stanford University Graduate School of Business in 2001 and graduated with both Arjay Miller Scholar honors and as the Arbuckle Award recipient.



## Jean Georges

Executive Director, Alzheimer Europe

Jean Georges is the Executive Director of Alzheimer Europe, a position he has held since November 1996. Mr Georges' role at Alzheimer Europe includes providing support for the Board, liaising with members or other European umbrella organisations, as well as managing of personnel, financial matters and overall project management of the various projects run by the organisation. Mr Georges has co-authored and contributed to several academic papers within the field of dementia and Alzheimer's. He has served as the Principal Investigator for Alzheimer Europe in projects supported by IMI (Innovative Medicines Initiative) and the European Union's Research and Innovation Funding Programmes: FP7 and Horizon2020. Prior to joining Alzheimer Europe, he served as a Parliamentary Assistant for members of the Luxembourg and European Parliaments and worked as a journalist in the European and International department of the Luxembourg newspaper "Tageblatt".



## Drew Holzapfel

Executive Director  
of The Global  
CEO Initiative on  
Alzheimer's Disease  
(CEOi)


Drew Holzapfel serves as the Executive Director of The Global CEO Initiative on Alzheimer's Disease (CEOi), a coalition of leading corporations investing in Alzheimer's disease research, treatment and care. He is also the Secretariat for the Davos Alzheimer's Collaborative, a multi-year initiative initiated by CEOi and The World Economic Forum in 2020. Drew is a Managing Partner at High Lantern Group. Over the course of his career, Drew has held positions in the federal government and with pharmaceutical companies, including Pfizer, The White House and US Department of Health and Human Services. As a Managing Partner at High Lantern Group, he opened the firm's Philadelphia office and has led the firm's work with top biopharmaceutical companies to drive market readiness, position key policy issues, build partnerships and gain third-party organization support. He also has helped many nonprofit/disease advocacy organizations and coalitions develop their positioning strategies and strengthen their influence and impact. Drew earned his Bachelor's degree from Emory University and a Master's of Business Administration from The University of Maryland.



## Jacqueline Hoogendam

Dementia policy co-ordinator on Long-Term Care, Ministry of Health, Welfare and Sport, The Netherlands

Jacqueline Hoogendam started her professional career as a lawyer in the private sector. In 1994 she switched to the Dutch government, the Ministry of Justice, with special responsibility on crime prevention and business ethics. After developing a chronic disease herself, she was offered a position at the Ministry of Health, Welfare and Sport in 2007. At the Department of Long Term Care she became responsible for dementia care. In the past years she extended this position to dementia policy co-ordinator for the entire ministry on both a national and an international level. As a part of this job, Jacqueline represents the Dutch government in, among others, the Executive Board of the Joint Programme Neurodegenerative Disease Research (JPND), the World Dementia Council and the European Governmental Group of Experts on Dementia.



## Professor Sean Kennelly

Consultant physician in geriatric and stroke medicine, Tallaght University Hospital


Professor Sean Kennelly is a consultant physician in geriatric and stroke medicine with a Doctor of Philosophy (PhD) specialising in Alzheimer's disease and brain health. He holds the following qualifications MB, BCh, PhD, FRCP(Lond), FRCPI. Professor Kennelly is a consultant physician in geriatric and stroke medicine in Tallaght University Hospital. He is the clinical lead for the older persons community/acute hospital integrated care service, and director of a specialist memory assessment service there. Sean is Clinical Associate Professor of Medical Gerontology in Trinity College, and a principal investigator in the Trinity College Institute of Neuroscience. A fellow of the Royal College of Physicians in London & Ireland, he has extensively published in his main research areas of Ageing, brain health and dementia. He has served as chief and principal investigator on several international clinical trials in early-stage Alzheimer's disease. He chairs the interdisciplinary Dementia Research Network Ireland (DRNI) and is a member of the clinical and research advisory panel for the Alzheimer's Society Ireland. He is a faculty member for the Global Brain Health Institute in Trinity College Dublin.



## Dr Ivan Koychev

Clinical academic psychiatrist, University of Oxford

Ivan Koychev is a clinical academic psychiatrist at the University of Oxford with a focus on the development of treatments for neurodegenerative disorders. His research experience spans the key components of neuroscience clinical trial methodology: conduct of proof-of-concept (PoC) biomarker-based clinical trials in surrogate populations, testing of repurposed compounds, development of stratification and efficacy biomarkers and creation of infrastructure for large-scale stratified recruitment into preclinical dementia experimental medicine studies and clinical trials. He has a particular interest in the development of scalable biomarkers for the detection of preclinical Alzheimer's disease using digital technologies, blood biomarkers and longitudinal health data. Clinically, he works as a Consultant Neuropsychiatrist focusing on the assessment and management of patients with neuropsychiatric presentations in acute medical settings.



### **Dr Giovanna Lalli**

Director of Scientific  
Affairs, UK Dementia  
Research Institute


Giovanna Lalli is the Director of Scientific Affairs of the UK Dementia Research Institute (UK DRI - <https://ukdri.ac.uk/about-us>), working on strategic development and partnerships, scientific initiatives, training/ career development activities. Giovanna holds MSc degrees in Chemistry and Pharmaceutical Technology (University of Bologna) and in Molecular Biology (University of Southern California). She obtained a PhD in Cell Physiology from University College London and has nearly 20 years of research experience, including a seven-year period as principal investigator and lecturer in molecular neurobiology at King's College London. Giovanna joined the UK DRI in September 2018, following three years as Senior Portfolio Developer at Wellcome overseeing the cellular and molecular neuroscience portfolio, supporting applicants and award holders, interacting with a wide range of UK and international stakeholders. While at Wellcome Giovanna also served for ten months as Acting Head of Neuroscience and Mental Health, developing new strategic funding initiatives in neuroscience research.



### **Lydia Lanman**

Senior Global Access  
Policy Leader,  
Hoffmann-La Roche


Lydia Lanman is the Senior Global Access Policy Leader at Hoffmann-La Roche and is responsible for global health policy efforts in neuroscience, rare disease, immunology, ophthalmology and influenza. Her area of expertise is brain health and Alzheimer's disease. Lydia joined the pharmaceutical industry in Canada in 2007, where she led a variety of national policy, government relations and market access efforts at two pharmaceutical firms. Prior to joining pharma, Lydia worked in various senior advisory roles in Canada, providing strategic advice directly to Ministers and Deputy Ministers of Health, both federally and provincially, on the development of health care policy, health system design and intergovernmental relations. Lydia holds a Bachelor of Arts in Political Science and a Master of Arts in Political Science/Public Health, both from the University of Alberta. Her graduate work focused primarily on Canadian and international health care reform.



## Professor Andrew CK Law

Professor of  
Psychiatry and Vice  
Dean, (International  
Student Services),  
Head, Department of  
Psychiatry  
Royal College of  
Surgeons in Ireland  
& University College  
Dublin (Malaysia  
Campus)

Andrew Law, MD, PhD, FRCPC received training in pharmacology and cardiovascular physiology at the University of Toronto and University of Cambridge prior to his medical education in St. Louis. He returned to Canada and pursued further studies on the effects of vascular disturbance in the pathogenesis of Alzheimer's disease at McGill University. He continued with postgraduate training in psychiatry at the University of Toronto and qualified as a specialist. Andrew joined the University of Hong Kong, founded the Neuro-dysfunction Research Laboratory and directed undergraduate education in psychiatry. Under his leadership, the laboratory attracted substantial funding for dementia research. Andrew was the Scientific Chair for the Chinese Dementia Research Association in Hong Kong and was active with community work related to elderly mental health. He has been elected Fellow by the American Psychiatric Association and the Royal College of Physicians of Edinburgh in recognition of his contributions in psychiatric teaching and research. Andrew then joined the Royal College of Surgeons in Ireland (Kuala Lumpur) as the Head of Department of Psychiatry and Honorary Senior Consultant in psychogeriatrics at Hospital Kuala Lumpur. Andrew is currently working with RCSI & UCD (Malaysia Campus), heading psychiatry and also the Vice Dean to oversee international relations. He is now conducting studies on Alzheimer's disease biomarkers, brain stimulation to treat behavioural symptoms in dementia, and the characteristics of cognitive impairments in an Asian indigenous population, involving collaborators from the UK, Malaysia, Hong Kong, and Thailand. From his Canadian training background, Andrew is an advocate of having primary care physicians as the principal care providers for individuals afflicted with common mental disorders, including dementia. He continues to work closely with public hospitals and non-government organizations on elderly mental healthcare and is an Advisor on Malaysia Ministry of Health's clinical treatment guidelines for dementia.



### **Dr Anja Leist**

Associate Professor  
in Public Health and  
Ageing, University of  
Luxembourg


Anja Leist is Associate Professor in Public Health and Ageing at the University of Luxembourg. Her research focuses on cognitive ageing and dementia, technology and ageing, and health inequalities from a social epidemiological and life course perspective. Anja is PI on several grants, among them a grant from the European Research Council, to pursue innovative research on cognitive ageing and dementia from a prevention and risk reduction perspective, with a focus on lifestyle behaviours and inequalities related to education and gender. Anja is elected Fellow of the Gerontological Society of America, and cofounder and advisor to the World Young Leaders in Dementia (WYLD) network that is now spanning 30 countries and 250+ professionals in the fields of dementia research, care, and innovation.



### **Dr Iracema Leroi**

Chief Investigator  
for the SENSE-Cog  
programme, GBHI

Iracema is an academic geriatric psychiatrist with a special interest in pragmatic interventions for the cognitive and neuropsychiatric aspects of neurodegenerative disorders, particularly Parkinson's disease and Alzheimer disease. Iracema is Chief Investigator for the SENSE-Cog programme which aims to understand the links among hearing, vision and cognitive impairment in older people in five European countries.



## **Dr Husseini Manji**

Global Head,  
J&J Science for Minds


Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases. Dr Manji has been inducted into the National Academy of Medicine, the World Economic Forum Global Future Councils and is a member of Harvard/MIT's Stanley Center SAB, amongst other appointments. He has received a number of awards including the NIMH Director's Career Award for Significant Scientific Achievement, and has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and development of novel therapeutics with over 300 publications in peer-reviewed journals, including Science and Nature Neuroscience.



## **Professor Soeren Mattke**

Research Professor of  
Economics at USC and  
the Director of the  
Center for Improving  
Chronic Illness Care

Soeren Mattke is a Research Professor of Economics at USC and the Director of the Center for Improving Chronic Illness Care, where he is running an observatory to evaluate health system preparedness for an Alzheimer's treatment globally. This work builds on his experience at the OECD Health Policy Unit in comparative health system analysis and benchmarking. Dr. Mattke is an expert in innovations to prevent, diagnose and manage chronic disease via better drugs, devices and technologies, improved delivery models and value-based payment, with over 150 published journal articles and technical reports. Prior to joining USC, Dr. Mattke led RAND Health's private sector practice and worked at the OECD in Paris, in the healthcare practice of Bain & Company in Boston, at Abt Associates, a policy consulting firm in Cambridge, MA, and at Harvard University. He trained as an internist and cardiologist at the University of Munich and got his doctoral degree in health policy at Harvard.



### **Maree McCabe**

Chief Executive  
Officer, Dementia  
Australia


Chief Executive Officer of Dementia Australia. A recognised leader in the health and aged care sector Maree brings extensive experience across the health, mental health and aged care sectors to her current role. Her career accomplishments include leading the successful unification of Alzheimer's Australia and rebranding to Dementia Australia, the development of technology at Alzheimer's Australia Vic, Executive roles in aged care and mental health. Maree is a member of a number of commonwealth and international health and aged care sector committees and Boards. Maree is a member of the Alzheimer's Disease International Asia Pacific Regional Committee and Chair of the Alzheimer's Disease International Nominations Committee.



### **Dr Pierre Meulien**

Executive Director,  
Innovative Medicines  
Initiative (IMI)

Dr Pierre Meulien is executive director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the program, which works to improve and accelerate the drug development process by facilitating collaboration between the key players involved in health research. Previously, Dr Meulien was president and CEO of Genome Canada, where he raised money and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that, he was chief scientific officer for Genome British Columbia and was the founding CEO of the Dublin Molecular Medicine Center. Dr Meulien also worked with the French biotechnology company Transgene and with Aventis Pasteur (now Sanofi Pasteur). He has a Ph.D. in molecular biology from the University of Edinburgh and carried out a postdoctoral fellowship at the Institut Pasteur in Paris



**Dr Cath Mummery**

Consultant neurologist leading the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery.


Cath Mummery is a consultant neurologist, and leads the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery. She is head of clinical trials at the Dementia Research Centre, University College London and has been chief investigator on over 20 early phase drug trials of potential disease modifying agents, including the ground-breaking platform trial DIAN-TU in presymptomatic individuals at risk of familial AD, and a first-in-human antisense oligonucleotide study, targeting MAPT to reduce tau in AD. She has a particular interest in early phase studies and genetic therapies, and in the psychological impact of trial participation. She sits on a number of advisory boards for potential disease modifying agents and for dementia service development. She is deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to the conduct of early phase trials in neurodegeneration.



**Dr Yoshiki Niimi**

Specially appointed lecturer, University of Tokyo

Special appointed lecturer, Unit for early and exploratory clinical development, University of Tokyo. Dr Niimi participates in the Japanese TRC-PAD (J-TRC) and the DIAN-Japan as a site PI at Tokyo university. He had worked at the Ministry of Health, Labour, and Welfare Japan as a senior specialist for dementia from 2012 till 2015. During that period, the G8 Dementia Summit and serial legacy events were held. He played a pivotal role in promoting the Global Dementia Legacy Event Japan and formulating the Japanese national dementia plan or 'New orange plan'. By utilizing this experience, he serves as the Vice-chair of the Social problem committee of the Japan Society for dementia research.



### **Professor Ricardo Nitrini**

Professor of Neurology,  
University of São Paulo  
Medical School


Ricardo Nitrini is a clinical neurologist with expertise in Behavioral and Cognitive Neurology. His academic career has been developed in the University of São Paulo Medical School, from graduation to full professor of Neurology. In the first years of his academic career he was strongly linked to teaching neurology and publishing books and chapters on books for undergraduate students. His initial areas of research were on infectious diseases such as neurosyphilis, neurosyphilis associated with HIV and prion diseases. Although he had published papers on behavioral and cognitive neurology from the beginning of his academic activities, only later on his research became more focused on epidemiological studies in dementia and in the diagnosis of dementia in low educated individuals. Among his most relevant contributions are tests designed for the diagnosis of cognitive impairment of illiterate and low educated individuals.



### **Professor Adesola Ogunniyi**

Professor of Medicine,  
University College  
Hospital, Ibadan

Adesola Ogunniyi is Professor of Medicine, College of Medicine, University of Ibadan and Consultant Neurologist to the University College Hospital, Ibadan. He has been actively involved with dementia research for three decades using a cross-cultural approach. He is the Chairman, College of Medicine Research and Innovation Management Unit. He received his medical education from University of Ife, Ile-Ife, residency training at UCH, and neuroepidemiology fellowship at the National Institutes of Health, USA. He is a fellow of the Nigerian and West African Postgraduate Colleges of Physicians. He is also a fellow of the Royal Colleges of Physicians of Edinburgh and London. He is well published and a reviewer for many journals.



## **Meera Pattabiraman**

Chair of the  
Alzheimer's and  
Related Disorders  
Society of India  
(ARDSI)


Meera Pattabiraman is Chair of the Alzheimer's and Related Disorders Society of India (ARDSI). She has been working in the field of dementia care, management and advocacy for the past 18 years. A post graduate in business administration, she entered the field of social work and dementia care because of her personal experience of being a carer for her father who had Alzheimer's disease. Meera Pattabiraman was part of the editorial board that produced the India Dementia Report in 2010, which is now used by the Ministry of Health and the Ministry of Social Justice and Empowerment as the reference guide in all matters relating to dementia. She is also part of the national think tank to develop better healthcare for the elderly and has taken part in national health policy meetings.



## **Dr Katherine Possin**

John Douglas  
French Alzheimer's  
Foundation Endowed  
Professorship at the  
UCSF Memory and  
Aging Center

Dr. Possin's research program is focused on improving the detection, diagnosis and care for people with neurodegenerative disease from diverse backgrounds and settings. She is the project lead of TabCAT, a software platform for tablet-based cognitive testing frequently used in research studies and clinical services. The Brain Health Assessment is a 10-minute assessment on TabCAT designed to help primary care providers to detect and diagnose Alzheimer's and related disorders. She also the principal investigator of the Care Ecosystem, a telephone-based supportive care program for persons with dementia and their caregivers. Throughout her work, she is dedicated to reducing healthcare disparities related to dementia. Recently, she exposed perils of race norms in neuropsychology, and race and ethnic disparities in dementia diagnosis. She currently holds the John Douglas French Alzheimer's Foundation Endowed Professorship at the UCSF Memory and Aging Center and the Global Brain Health Institute.



### **Dr Gil Rabinovici**

Edward Fein and Pearl Landrith Distinguished Professor, Departments of Neurology and Radiology, University of California San Francisco (UCSF)


Dr Gil Rabinovici is the Edward Fein and Pearl Landrith Distinguished Professor in the University of California San Francisco (UCSF) Departments of Neurology and Radiology. He received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed neurology residency and behavioral neurology fellowship training at UCSF. Dr Rabinovici's research focuses on utilizing multi-modal neuroimaging techniques and other biomarkers to improve early detection and diagnostic accuracy in dementia, and to study mechanisms of neurodegenerative diseases. He is Associate Director of the UCSF Alzheimer's Disease Research Center, serves as Study Chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies and co-PI of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), among other activities. Dr Rabinovici's work is supported by the National Institutes of Health, the Alzheimer's Association, the American College of Radiology, the Rainwater Charitable Foundation and industry partners.



### **Dr Tim Raemaekers**

Programme Officer Neurodegeneration, European Commission (EU)

Tim Raemaekers joined DG Research & Innovation at the European Commission in 2019 where he works on policy development in the area of neuroscience. Prior to this, and since 2014, he worked for the European Commission's DG Joint Research Centre in Italy where he supported projects in the areas of biotechnology and medical technology. He particularly worked on a project aimed at developing and improving tools for a coherent, safe and effective management of medical devices in Europe. He was trained as a bioengineer in cell and gene biotechnology and holds a PhD in the Medical Sciences from the University of Leuven (Belgium). His doctoral work on cancer cell biology led to the discovery of an essential gene for cell division. As a postdoc, he studied the cell biology of neuronal synapse formation and degeneration at the VIB Centre for the Biology of Disease (Belgium).



**Professor  
Vijayalakshmi  
Ravindranath**

Professor, Centre for  
Brain Research


Dr. Vijayalakshmi Ravindranath obtained her Ph.D from the University of Mysore in 1981. In 1986, after completing her post-doctoral training at the National Institutes of Health, USA, she joined the Department of Neurochemistry at National Institute of Mental Health and Neurosciences, (NIMHANS) Bangalore. In 1999, the Dept. of Biotechnology (DBT), Government of India sought her out to help establish the National Brain Research Centre (NBRC), an autonomous institution of DBT, Ministry of Science and Technology as a centre of excellence and to co-ordinate and network neuroscience research groups in the country. She continued as Founder Director, NBRC till May 2009, when she returned to Bangalore at the Indian Institute of Science (IISc) as Professor and Founder Chair of the newly created Centre for Neuroscience. She is currently Founder Director, Centre for Brain Research (CBR) at Indian Institute of Science. The newly established Centre for Brain Research is a unique public-private partnership between IISc (a public funded institution) and Pratiksha Trust (a philanthropy) that funds CBR.



**Professor  
William  
Reichman**

President and Chief  
Executive Officer,  
Baycrest

Dr. William E. Reichman is President and Chief Executive Officer of Baycrest, among the world's premier academic health care organizations focused on seniors health and residential care and aging brain function. Dr. Reichman has an appointment as Professor of Psychiatry on the Faculty of Medicine at the University of Toronto and is a recipient of an honorary degree of laws from OCAD University. He is a noted global authority on the delivery of innovative medical, mental health and dementia services in geriatric care settings. Dr. Reichman is currently President of the International Psychogeriatric Association and has advised the World Health Organization and the governments of Canada, the United States and China on health policy. He is Co-Chair of Canada's Ministerial Advisory Board on Dementia and has been instrumental in the development of Canada's National Dementia Strategy.



## **Professor Martin Rossor**

NIHR National Director for Dementia Research, UCL Queen Square Institute of Neurology


Martin Rossor is the NIHR National Director for Dementia Research, Professor Emeritus, and Principal Research Associate at the UCL Queen Square Institute of Neurology. Following his training in clinical neurology at the National Hospital, Queen Square, Martin undertook primary research on the neurochemistry of degenerative dementia at the MRC Neurochemical Pharmacology Unit, Cambridge, before being appointed as Consultant Neurologist at St. Mary's Hospital London and the National Hospital in 1986. Martin was appointed as the Chairman of the Division of Neurology in 2002, after becoming Professor of Clinical Neurology. He established a specialist cognitive disorders clinic, which acts as a tertiary referral service for young onset and rare dementias. Martin's clinical research interests are in the degenerative dementias, particularly familial disease, and more recently in general cognitive impairment in systemic disease and multimorbidity.



## **Professor James Rowe**

Professor of Cognitive Neurology and Director of Cambridge Centre for Frontotemporal Dementia and Related Disorders, University of Cambridge

As Professor of Cognitive Neurology, James Rowe studies the mechanisms and potential treatments for frontotemporal dementia, Progressive Supranuclear Palsy and Alzheimer's disease. He trained in medical sciences and experimental psychology at Cambridge, before clinical studies in Oxford and his PhD at the Institute of Neurology, London. After further specialist training in Copenhagen, he returned to Cambridge in 2005. He is Associate Director of DPUK, leading the academic-industrial partnership for experimental medicine. He leads the Centre for Frontotemporal Dementia and the Clinical program within the Centre for Parkinson-plus, together with regional NHS clinics for these disorders. The integration of multimodal brain imaging, genetics, pharmacology and computational modelling provides a powerful platform to understand neurological disease, and to assess the efficacy of novel treatments.



### **Ivana Rubio**

Vice President, Global and US Alzheimer's Disease Medical at Biogen


Ivana Rubino is the Vice President, Global and US Alzheimer's Disease Medical at Biogen. A born and bred Italian, Ivana has spent many years working in the Alzheimer's field to advance the science and the clinical practice to optimize the management of people living with this devastating disease. She is a member of multiple pre-competitive initiatives. Ivana holds a double Master's Degree in Molecular Biology and Genetics and a PhD in Immunogenetics.



### **Dr Gustavo Saposnik**

Associate Professor of Medicine at the University of Toronto

Dr. Gustavo Saposnik is a neurologist, senior scientist, and associate Professor of Medicine at the University of Toronto interested in clinical outcomes and Decision neuroscience research. Gustavo is the founder and director of NeuroEconSolutions.com, a company that aims at improving clinical outcomes through cost-effective, high impact and innovative research by applying principles from behavioral economics into clinical care across Canada (and Worldwide). Following his PhD in Decision Neuroscience (2020) at the University of Zurich, Gustavo gained experience in understanding how physicians make decisions. He created a platform applying concepts from Neuroeconomics to facilitate research studies by assessing physicians and patients' factors associated with suboptimal decisions and therapeutic inertia (TI). His team developed and tested in a RCT the efficacy of an educational intervention (applying the traffic light system strategy) that showed 70% reduction of TI. He used AI-based software for emotional recognition and eye-trackers while physicians made treatment choices to evaluate specific pathways that contribute to TI. Gustavo's international leadership in outcomes research and decision neuroscience is reflected by grants (over 30 as PI), personal awards, over 280 peer-reviewed publications, international collaborations, guidelines development, and invitations as visiting professor.



### **Professor Charles Scerri**

Professor of Dementia Studies at the Faculty of Medicine and Surgery, University of Malta


Charles Scerri is a professor of Dementia Studies at the Faculty of Medicine and Surgery, University of Malta. He is the Chairperson of the Malta Dementia Society, Chairperson of the National Dementia Working Group, Vice-Chair of Alzheimer Europe and National Focal Point on Dementia in Malta. He is also a member of the European Union Joint Programme for Neurodegenerative Diseases (JPND) Scientific Advisory Board and Early Detection and Timely Intervention in Dementia Group (INTERDEM). Amongst his latest contributions is the national dementia strategy document Empowering change: A National Strategy for Dementia in the Maltese Islands (2015-2023).



### **Nora Super**

Senior Director of the Milken Institute Center for the Future of Aging (CFA)

Nora Super is the Senior Director of the Milken Institute Center for the Future of Aging (CFA) where she elevates awareness, advances solutions, and catalyzes action to promote healthy longevity and financial wellness. Super is also the Executive Director of the Milken Institute Alliance to Improve Dementia Care. Launched in 2020, the Alliance to Improve Dementia Care seeks to transform and improve the complex health and long-term care systems that people at risk for and living with dementia must navigate. Nora is a respected thought leader, frequent speaker, and prolific writer on healthy longevity and the economic and social impact of global population aging. From 2014-2016, Nora served as the Executive Director of the White House Conference on Aging, where she received wide recognition for her nationwide efforts to improve the lives of older Americans. She has also held leadership roles at the U.S. Department of Health and Human Services, AARP, Kaiser Permanente, and the National Association of Area Agencies on Aging.



### **Dr Elina Suzuki**

Advisor to the Director of Employment, Labour and Social Affairs, OECD


Elina Suzuki is an Advisor to the Director of Employment, Labour and Social Affairs at the Organisation for Economic Co-operation and Development in Paris. Her work focuses primarily on dementia, ageing, long-term care, and the use of new digital tools for health. She co-authored the recent OECD report *Care Needed: Improving the Lives of People with Dementia*, which presents the most up-to-date and comprehensive cross-country assessment of the state of dementia care in OECD countries. Prior to joining the OECD, Elina worked at SEEK Development in Berlin. She graduated from McGill and Harvard.



### **LiYu Tang**

Secretary General and co-founder of the Taiwan Alzheimer's Disease Association (TADA)

Li-Yu Tang is Secretary General and co-founder of the Taiwan Alzheimer's Disease Association (TADA), and is a member of the Long-Term Care Committee of the Executive Yuan of Taiwan. She has over 28 years' experience in dementia research, practice and training. While at TADA, Li-Yu Tang has set up a toll-free helpline service, caregiver support groups and training programmes and a national dementia social support centre. She has created health promotion programmes for people with dementia and their care givers and provided training and coaching to more than sixty organisations throughout the country to help them deliver the programmes. She is also a consultant to Taipei City Government and is a member of a long-term care committee of four city governments in Taiwan.



## Dr Rudolph Tanzi

Director of the Genetics and Aging Research Unit and Professor of Neurology, Harvard Medical School


Dr Rudolph Tanzi is the Director of the Genetics and Aging Research Unit, Co-Director of the McCance Center for Brain Health, Co-Director of the MassGeneral Institute for Neurodegenerative Disease, and Vice-Chair of Neurology (Research), at Massachusetts General Hospital, and the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr Tanzi discovered the first three Alzheimer's disease genes and the first neuroinflammation-related Alzheimer's gene, CD33. He is developing therapies for treating and preventing AD using human his laboratory's brain organoid models. Dr Tanzi has published nearly 600 papers, received numerous awards, including the Metropolitan Life Award, Potamkin Prize, Smithsonian American Ingenuity Award, and was one of the TIME100 Most Influential People in the World. Dr Tanzi is a New York Times bestselling author, who co-authored "Decoding Darkness" "Super Brain", "Super Genes", and "The Healing Self" with Deepak Chopra. He has also hosted three PBS shows and made numerous appearances on network and cable news and medical television shows. In his spare time, he plays keyboards for Joe Perry, Aerosmith and other musicians.



## Professor Mathew Varghese

Professor of Psychiatry, National Institute of Mental Health & Neuro Sciences, India

Dr Mathew Varghese has been a faculty at the Department of Psychiatry, NIMHANS, Bangalore, India for over 30 years. He was the Head, Department of Psychiatry from 2013 to 2016 and is currently Head, Geriatric Psychiatry Services and the Geriatric Clinic at NIMHANS. Dr Varghese's areas of research are in Geriatric Psychiatry (mainly dementias), Epidemiology and Community Psychiatry, Family interventions and Rehabilitation. He was a founding member of the International 10/66 Dementia Research Group. He co-wrote and edited the Dementia India Report, 2010 and Dementia India, 2020. He was one of the Indian Co-Investigators on the World Mental Health Survey (2006) and was a Principle Investigator on the National Mental Health Survey of India, 2016. Currently he is a collaborator on the Longitudinal Ageing Study of India (LASI). He has over 150 publications in journals, monographs, and books on various cross-cultural aspects of mental health in developing countries.



### **Dr Isabelle Vedel**

Associate Professor  
in the Department of  
Family Medicine at  
McGill University


Dr Isabelle Vedel, MD, PhD, is an Associate Professor in the Department of Family Medicine at McGill University, as well as a public health physician. She is the co-founder, and scientific director of the pan-Canadian research team “Research on the Organization of Health Services for Alzheimer” (ROSA). She is responsible for the evaluation of the Alzheimer’s plan in Quebec and participated as an expert with the Canadian Academy of Health Sciences to support the development of the national strategy on dementia. She is also a co-PI of an international JPND project “CO-desiGning demeNtia dIagnoSis ANd post-diagnostic CarE (COGNISANCE).



### **George Vradenburg**

Co-Chair,  
Davos Alzheimer’s  
Collaborative

George Vradenburg serves as Co-Chair of the Davos Alzheimer’s Collaborative, a coalition focused on driving global scientific, business, policy and financial coordination in Alzheimer’s preparedness, co-convened in January 2020 by the Global CEO Initiative on Alzheimer’s Disease (CEOi) and the World Economic Forum. In this role, George provides general oversight and advocacy and works to ensure the Collaborative remains sustainable and action-oriented. George is the Chairman and Co-Founder of UsAgainstAlzheimer’s (UsA2), a disruptive and catalytic force committed to stopping Alzheimer’s by 2020. In 2011, the United States Secretary of the Department of Health and Human Services named George to serve on the National Alzheimer’s Advisory Council on Research, Care and Services for the first-of-its-kind National Alzheimer’s Strategic Plan. George received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. from Harvard Law School, cum laude.



## Professor Huali Wang

Professor and Chair for Clinical Research, Director of the Dementia Care and Research Center, and Associate Director of Beijing Dementia Key Lab, Peking University Institute of Mental Health


Dr Huali Wang is Professor and the Chair for Clinical Research, Director of the Dementia Care and Research Center, and Associate Director of Beijing Dementia Key Lab, Peking University Institute of Mental Health. She established the first dementia caregiver support group in China in 2000. Now she directs a training program for community doctors and service providers, and a train-the-trainer program for dementia caregivers support in China. She published five books on dementia care, including Smart Caregivers, China Memory Clinic Guideline and Practice Manual on Psychological Support for Older Adults. The care model has been partly adopted by WHO West Pacific Regional Office to develop the toolkit for community-based dementia care in low- and middle-income countries. Dr Wang is leading the National Platform on Clinical Dataset and Biobank of Major Mental Disorders. In regard to biomarker research of Alzheimer's Disease, she found that ApoE4 allele potentially modulates the hippocampal connectivity and the brain functional connectome.



## Ninie Wang

Founder CEO of Pinetree Care Group

Ninie Wang is Founder CEO of Pinetree Care Group, focusing on business model innovation, evidence-based care and talent development in providing restorative, integrated care continuum for the aging population since 2004. Ninie is actively involved in domestic and international initiatives promoting healthy aging-related research, practice and policy. She is also member of World Economic Forum Global Future Council on Health and Healthcare, Young Global Leaders, Aspen Institute China Fellow, France-China Young Leaders. Ninie is currently a Johns Hopkins University - Tsinghua University DrPH candidate, has a BA Econ. from UIBE, and MBA from INSEAD."



**Professor Henrik Zetterberg**

Professor of  
Neurochemistry,  
University of  
Gothenburg

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and leads the UK DRI Fluid Biomarker Laboratory at UCL. His main research focus and clinical interest are fluid biomarkers for brain diseases, Alzheimer’s disease in particular. He has published more than 1300 scientific articles and received numerous awards.

The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

[worlddementiacouncil.org](http://worlddementiacouncil.org)

© 2021 World Dementia Council  
UK charity registration number: 1170743

Cover image editorial credit: Shutterstock.com

